The article discusses research on the splicing of ribonucleic acids to boost the treatments of cancer patients. Topics covered include the hyperactivation and alteration of MYC. Also mentioned is the role of BUD31 in the survival of cells and intron retention that could enhance the survival odds of cancer patients.